Aspire Biopharma Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aspire Biopharma Holdings, Inc. (ASBP) on January 6, 2026, covering events occurring on January 1, 2026. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Estero, Florida. The filing primarily addresses the entry into material definitive agreements regarding debt restructuring.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, operating margins, or total liquidity positions. The only specific financial figure disclosed relates to the debt restructuring transaction:
- Debt Exchange Amount: Approximately $1.75 million in debt is being exchanged for common stock.
- Debt Origin: The debt was incurred by the company's predecessor, PowerUp Acquisition Corp., under subscription agreements dated March 4, 2024, and May 9, 2024.
Material Changes
The primary material change is the conversion of approximately $1.75 million of outstanding debt into equity. Key terms of this change include:
- Exchange Mechanism: Holders may exchange debt for common stock at a price equal to the closing stock price on the trading day prior to the exchange notice, less a $0.01 administrative fee.
- Restrictions: Each holder may submit up to four exchange notices, with each notice limited to 30% of their outstanding balance. All notices must be submitted by January 31, 2026.
- Share Status: Issued shares will be freely tradeable and free of transfer restrictions or legends.
- Financing Rights: In the event of a financing exceeding $3,000,000, holders may elect to receive cash proceeds equal to 25% of their outstanding balance, or up to 33.33% of the aggregate financing proceeds.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard legal disclaimers. The transaction relies on exemptions from registration under Section 3(a)(9) of the Securities Act and Regulation D. The company represents that the holders are "accredited investors."
Investor Verification Checklist
- Verify the exact number of shares issued upon the completion of the debt exchange.
- Confirm the impact of the $1.75 million debt reduction on the company's total outstanding debt and balance sheet.
- Monitor the company's stock price to determine the final exchange price and total equity dilution.
- Review the full text of the Exchange Agreement (Exhibit 10.1) for specific covenants and conditions.
- Assess the likelihood of a future financing exceeding $3,000,000 that would trigger cash repayment options for holders.